Wyeth Will Not Reintroduce RotaShield; NIAID Study Says Risk Is Low
Executive Summary
Wyeth-Ayerst has no plans to reintroduce the rotavirus vaccine RotaShield, the company said Oct. 12 after the National Institute of Allergy & Infectious Diseases announced results of a study suggesting that the increased risk of intussusception associated with the vaccine may be offset by a decreased risk over time.
You may also be interested in...
Wyeth Prevnar Supply “Bottleneck” Will Let Up In Mid-2002, Firm Says
Wyeth-Ayerst hopes to wrap-up discussions with FDA over the product release process for Prevnar to alleviate a supply "bottleneck" by mid-2002
Wyeth Prevnar Supply “Bottleneck” Will Let Up In Mid-2002, Firm Says
Wyeth-Ayerst hopes to wrap-up discussions with FDA over the product release process for Prevnar to alleviate a supply "bottleneck" by mid-2002
Wyeth Withdraws RotaShield Ahead Of Rotavirus Season And ACIP Review
Wyeth-Lederle Vaccines is withdrawing the RotaShield rotavirus vaccine because recently gathered epidemiological data continue to suggest links to intussusception.